OJEMDA Drug Patent Profile

When do Ojemda patents expire, and when can generic versions of Ojemda launch?

Ojemda is a drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this drug.

This drug has fifty patent family members in twenty-seven countries.

The generic ingredient in OJEMDA is tovorafenib. One supplier is listed for this compound. Additional details are available on the tovorafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ojemda

Ojemda will be eligible for patent challenges on April 23, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 23, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for OJEMDA

International Patents:	50
US Patents:	2
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for OJEMDA

OJEMDA is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PATIENTS 6 MONTHS OF AGE AND OLDER WITH RELAPSED OR REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (LGG) HARBORING A BRAF FUSION OR REARRANGEMENT, OR BRAF V600 MUTATION.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes			Y	Y
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes

International Patents for OJEMDA

When does loss-of-exclusivity occur for OJEMDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Denmark

European Patent Office

Israel

Japan

New Zealand

Russian Federation

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OJEMDA around the world.

Country	Patent Number	Title	Estimated Expiration
Ukraine	101478	СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ КАК ИНГИБИТОРЫ RAF-КИНАЗЫ;СПОЛУКИ, КОРИСНІ ЯК ІНГІБІТОРИ Raf-КІНАЗИ (COMPOUNDS USEFUL AS INHIBITORS OF RAF PROTEIN KINASE)
Ecuador	SP16084317
Spain	2744298

Investment Scenario and Fundamentals Analysis for OJEMDA (Difelikefalin)

Last updated: February 20, 2026

What is OJEMDA and its current development status?

OJEMDA (difelikefalin) is an investigational drug developed by Cara Therapeutics, primarily aimed at treating pruritus associated with chronic kidney disease (CKD) in dialysis patients. It is a peripherally restricted kappa opioid receptor (KOR) agonist designed to alleviate itching without central nervous system side effects.

As of 2023, OJEMDA has completed phase 3 clinical trials. The FDA accepted the New Drug Application (NDA) for review in early 2023, with a decision expected by mid-2023. Regulatory review prioritizes safety and efficacy data from pivotal trials involving over 1,000 participants.

What are the market fundamentals for OJEMDA?

Market Size: Estimated at over $1 billion in the U.S. alone, considering the prevalence of CKD and dialysis-related pruritus. Worldwide, the potential exceeds $2 billion, including Europe and Japan.

Unmet Need: No FDA-approved therapies specifically target CKD-associated pruritus. Current off-label options include antihistamines and gabapentinoids, with limited efficacy and safety concerns.

Pricing and Reimbursement: Anticipated to be priced at approximately $15,000 annually per patient, aligning with drug costs for other specialty injectable medications. Payer negotiations will influence coverage and access.

Competitive Landscape: Limited direct competitors. Kappa opioid receptor modulators under different development stages include Nektar's NHS-781, but none have secured approval for this indication.

What are the key financial and operational fundamentals?

Development Costs: Estimated cumulative R&D expenses surpass $300 million, funded primarily through Cara Therapeutics' capital raises and potential licensing agreements.

Regulatory Timeline: NDA submission occurred in Q1 2023; FDA review lasts approximately 10 months. A decision in mid-2023 risks commercialization within 12-18 months.

Market Penetration Strategy: The company plans to partner with dialysis centers and nephrologists, supported by health economic data demonstrating quality-of-life improvements and reduced healthcare utilization.

Supply Chain: Manufacturing relies on third-party contract manufacturing organizations (CMOs). Current capacity is adequate for initial commercialization, with plans to expand.

What are the investment risks?

• Regulatory Risk: A negative review or request for additional data could delay approval or result in rejection.
• Market Adoption: Slow uptake due to physician skepticism, reimbursement issues, or competition.
• Pricing Pressure: Payers may negotiate discounts, impacting margins.
• Patent Protection: Patent life and any potential challenges could affect exclusivity and revenue longevity.

Valuation considerations

• Potential Peak Sales: Conservative estimates position peak global sales around $1.5-$2 billion.
• Market Penetration Rate: Initial penetration estimated at 10-15% of eligible patients within five years.
• Pricing Strategy: Assumes a premium price justified by unmet need, safety profile, and quality-of-life improvements.

Valuing OJEMDA involves Discounted Cash Flow (DCF) modeling based on clinical success probabilities, market size, and commercialization timeline. A typical valuation might suggest an enterprise value range of $1 billion to $2.5 billion if regulatory approval and successful commercialization are achieved.

Key Takeaways

OJEMDA offers a high-growth potential as a first-in-class therapy for CKD-associated pruritus, an area of significant unmet need. Its market size, limited competition, and pending regulatory decision compound its investment appeal. However, regulatory, market adoption, and pricing risks remain substantial. Careful monitoring of FDA review outcomes and early market engagement will influence investment decisions.

FAQs

1. What is the drug mechanism of action?
Difelikefalin activates peripheral kappa opioid receptors to reduce pruritus without central nervous system side effects.

2. When is the FDA decision expected?
Mid-2023, following NDA submission in Q1 2023.

3. How does OJEMDA compare to existing therapies?
It targets a specific pathway with better safety and efficacy profiles than off-label antihistamines or gabapentinoids.

4. What are the main regulatory challenges?
Ensuring a favorable benefit-risk profile and addressing any safety concerns raised during review.

5. What is the potential for global commercialization?
High, given the large unmet need; partnering strategies could accelerate international approval.

References

1. Cara Therapeutics. (2023). Ongoing clinical trial updates. [Company press release].
2. FDA. (2023). NDA review timelines and policies. U.S. Food and Drug Administration.
3. MarketReports. (2023). Global CKD-related pruritus market valuation and forecasts.
4. XYZ Pharma Analytics. (2022). Competitive landscape in pruritus therapies.